Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 163

Results For "Import"

2005 News Found

Abbott recalls powder formula manufactured at Sturgis, Mich., plant
News | February 19, 2022

Abbott recalls powder formula manufactured at Sturgis, Mich., plant

Recall does not include any metabolic deficiency nutrition formulas


Ligand posts strong 2021 performance
News | February 18, 2022

Ligand posts strong 2021 performance

Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.


Moderna’s Covid-19 vaccine approved in Australia for children (6-11 years)
News | February 17, 2022

Moderna’s Covid-19 vaccine approved in Australia for children (6-11 years)

Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia


IPP to organize e-conference on 'Indian Pharma Industry: Developing a conducive ecosystem' on Feb 18
News | February 17, 2022

IPP to organize e-conference on 'Indian Pharma Industry: Developing a conducive ecosystem' on Feb 18

The speakers for the e-conference are: Dr. Mukund Chorgade, President/CSO, THINQ Pharma; Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance; Jayaseelan J., National Vice President (Industry Division), Indian Pharmaceutical Association; Spandan Mishra who is Director- Sales, Customer Service & Logistics for Evonik India, Nepal & Sri Lanka region; Dr. Kommu Nagaiah, Chief Scientist & Head, CSIR-IICT; Govind K. Jaju, Partner, Suingora Consulting; nd Pravin Prashant, Executive Editor, Indian Pharma Post & Editor, Indian Chemical News.


Kato wins USFDA approval for studies in retinal disorder
Biotech | February 17, 2022

Kato wins USFDA approval for studies in retinal disorder

Resolv ER may remedy leading causes of blindness in adults


PerkinElmer’s SIRION Biotech and CRG to develop diabetes gene therapy
Biotech | February 17, 2022

PerkinElmer’s SIRION Biotech and CRG to develop diabetes gene therapy

Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy


USFDA accepts for Priority Review Bristol Myers Squibb’s Supplemental BLA for Breyanzi
Biotech | February 17, 2022

USFDA accepts for Priority Review Bristol Myers Squibb’s Supplemental BLA for Breyanzi

Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years


BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies
interviews | February 15, 2022

BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies

BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post


Lynparza plus abiraterone effective in standard-of-care in 1st-line metastatic castration-resistant prostate cancer
Biotech | February 15, 2022

Lynparza plus abiraterone effective in standard-of-care in 1st-line metastatic castration-resistant prostate cancer

These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium


UFlex introduces a range of innovative and sustainable packaging solutions
Packaging | February 15, 2022

UFlex introduces a range of innovative and sustainable packaging solutions

Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021